【摘要】 目的研究重复经颅磁刺激(rTMS)与帕罗西汀联合治疗抑郁焦虑共病患者中的临床疗效及临床价值。方法方便选取2018年3月—2019年3月该院门诊及病房收治的抑郁焦虑共病患者60例,随机分为研究组(n=30例,rTMS联合帕罗西汀进行治疗)和对照组(n=30例,单用帕罗西汀进行治疗),对两组患者的HAMA评分、HAMD-17评分、治疗总有效率及认知功能等进行统计对比。结果治疗2周、4周后,研究组的HAMA评分(14.65±0.23)分、(7.61±1.04)分、HAMD-17评分(18.34±3.47)分、(9.37±2.43)分均较对照组(17.06±1.15)分、(10.01±2.96)分、(18.62±4.04)分、(14.43±3.43)分低(t=11.256、4.190、8.492、7.896,P<0.05);且研究组治疗后认知功能改善情况[电位P300潜伏期与其波幅潜伏期(315.66±10.32)ms、波幅(4.16±0.87)μv、眼动测定NEF(28.41±2.52)、RSS(6.26±1.09)]优于对照组[(342.78±26.98)ms、(2.69±0.41)μv、(26.21±3.04)、(5.21±0.31)],差异有统计学意义(t=5.142、8.372、3.052、5.075,P=0.10、0.009、0.019、0.010)。结论对抑郁焦虑共病患者积极采取rTMS联合帕罗西汀口服治疗,可以显著改善患者抑郁焦虑情绪,改善其认知功能,该疗法值得推崇运用。更多还原

【Abstract】 Objective To study the clinical efficacy and clinical value of repeated transcranial magnetic stimulation(rTMS) combined with paroxetine in the treatment of patients with comorbid depression and anxiety. Methods Convenient select Sixty patients with depression and anxiety co-morbidity admitted in the hospital from March 2018 to March 2019 were randomly divided into study group(n=30 cases, rTMS combined with paroxetine for treatment) and control group(n =30 cases, treated with paroxetine alone). The HAMA score, HAMD-17 score, total effective rate and cognitive function of the two groups of patients were statistically compared. Results After 2 and 4 weeks of treatment, the HAMA score of the study group was(14.65 ± 0.23) points,(7.61 ± 1.04) points, the HAMD-17 score(18.34±3.47) points, and(9.37±2.43) points were all better than the control group(17.06 ±1.15) points,(10.01 ±2.96) points,(18.62 ±4.04)points,(14.43 ±3.43)points lower(t =11.256,4.190,8.492,7.896,P<0.05); and the cognitive function of the study group was improved after treatment [potential P300 latency and its amplitude latency(315.66±10.32) ms, amplitude(4.16±0.87) μv, eye movement measurement NEF(28.41 ±2.52), RSS(6.26 ±1.09)], better than the control group [(342.78 ±26.98) ms,(2.69 ±0.41) μv,(26.21 ±3.04),(5.21 ±0.31)], the differences were statistically significant(t =5.142,8.372,3.052,5.075,P =0.10,0.009,0.019,0.010). Conclusion Actively taking rTMS combined with paroxetine in patients with depression and anxiety comorbidities can significantly improve patients’ depression and anxiety and improve their cognitive function. This therapy is worthy of application.更多还原